SPOTLIGHT -
Higher MRD Threshold Could Guide Discontinuation of Myeloma Maintenance
Ben Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.
Goals of an MRD-Based Discontinuation Trial in Multiple Myeloma
Ben Derman, MD, discussed the rationale for an ongoing clinical trial evaluating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.
